Skip to main content

Table 2 Characteristics of Children and Adolescents with Endemic KS in Context of a Pediatric-Specific Staging Classification

From: Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease

  Stage 1: Mild/Moderate Cutaneous/Oral KS Stage 2: Lymphadenopathic KS Stage 3: Woody Edema KS Stage 4: Visceral and/or Disseminated Cutaneous/Oral KS
Number of patients, n 4 6 6 4
Baseline Anemia (hgb < 8), n (%) 0 5 (83%) 1 (17%) 3 (75%)
Baseline Thrombocytopenia (platelet count < 100), n (%) 1 (25%) 4 (67%) 0 3 (75%)
Alive in complete remission, n (%) 3 (75%) 5 (83%) 1 (17%) 0
Alive with stable disease, n (%) 0 0 3 (50%) 1 (25%)
Deaths, n (%) 1 (25%) 1 (17%) 2 (33%) 3 (75%)
 KS related death 0 1 2 3
 Non-KS related death 1 0 0 0
2-year EFS in HIV+ KS cohorta too few patients to determine 73% 29% 0
2-year OS in HIV+ KS cohorta 75% 79% 12%
  1. Legend: KS Kaposi sarcoma, hgb hemoglobin, EFS event-free survival, OS overall survival, areferences the published historical HIV-related pediatric KS cohort (reference number 17)